Patrick Duxbury

Patrick Duxbury helps clients to research, develop, manufacture and sell pharmaceutical, biotech and medical device products, using his extensive experience of structuring and executing transactions in the life sciences sector.

Patrick was a microbiologist and geneticist before re-qualifying as a lawyer in 1993 with first class honours. He now specialises in all aspects of transactional work in the life sciences sector. He has helped clients including Argenx, AstraZeneca, Astellas, MedImmune, Astex Therapeutics, Crescendo Biologics, Epidarex, ERS Genomics, GlaxoSmithKline (GSK), Heptares Therapeutics, Kymab, Immunocore and SROne on significant M&A transactions, licensing and collaboration deals and fundraisings.

Thanks to his deep knowledge of the world in which he operates, Patrick delivers his clients a unique mix of regulatory, antitrust, IP, corporate and dispute resolution advice, helping many of the sector's key players.

Deal highlights include advising AstraZeneca on its landmark collaboration agreement for the development and distribution of the University of Oxford's potential COVID-19 vaccine, a $6.9 billion cancer drug collaboration agreement with Daiichi Sankyo Company Limited, an $8.5bn oncology deal with Merck, on AstraZeneca's $300 million disposal of the rights to cancer drug Caprelsa to Genzyme and its $1.275bn collaboration with Innate Pharma. He has also recently advised Heptares Therapeutics Limited and Argenx BV, and Immunocore on several strategic license and collaboration transactions.

Patrick is a well-known speaker on topics relating to transactions in the life sciences sector. He teaches on the BIO Advanced Business Development Course in both the US and Europe.


Patrick is ranked as the only 'Star Individual' for Life Sciences: Transactional in Chambers UK 2020 and is ranked as an IP Star in the 2020 edition of Managing Intellectual Property. In this same year he won 'Financial & Corporate Lawyer of the Year: Licensing & Collaboration' in the LMG European Life Sciences Awards 2020 and achieved recognition by being ranked among the foremost patent practitioners in the IAM Global Leaders guide (the guide features those professionals who have been ranked in the gold tier of IAM Patent 1000).

Patrick is also ranked in the Who's Who Thought Leader for Life Sciences publication and received 'Life Sciences - Transactional Lawyer of the Year 2019' at the prestigious, international, Who's Who Legal Awards 2019. He has since been named in Who's Who Legal: Thought Leaders Global Elite 2022 for 'Life Sciences – Transactional', recognising him among the top 2% of all Who's Who Legal-recognised legal practitioners from around the world.

"Patrick Duxbury is known for his deft handling of complex technology transfer, research and collaboration agreements, indeed all manner of IP-driven transactions. A source says: 'He is a leading light and has made a considerable difference to the sector over may decades.' " Chambers UK 2020.

Patrick was recognised as a 'transactions star' in the UK in the 2020 'IP Stars' guide, produced by Managing Intellectual Property.

The Gowling WLG UK IP transaction team won the IP Transaction Team of the Year Award from MIP in 2018 and TMT team of the year at the British Legal Awards 2018 on the back of their work for AstraZeneca on its deal with Merck.


  • Patrick has represented AstraZeneca on a large number of transactions including, most recently, their landmark collaboration agreement for the development and distribution of the University of Oxford's potential COVID-19 vaccine. He also advised AstraZeneca on the disposal of the rights to cancer drug Caprelsa to Genzyme and on its $8billion collaboration with Merck in the IO space. This transaction also won the Scrip licensing deal of the year for 2018.
  • Working with Cambridge Antibody Technology Group (and now MedImmune) over the 15 years on numerous business-critical licence and collaboration deals including transactions with Amgen, Dyax, Micromet, Wyeth and Merck. Patrick acted for MedImmune on its widely publicised in-licence of the Phase III antibody, Tremelimumab, from Pfizer and its five antibody product deal with Amgen, which was one of the biggest deals of 2012.
  • Patrick has known Astex Therapeutics for many years and has helped the company through all of its significant transactions, including its widely publicised licence and collaboration deals with AstraZeneca, Novartis ( which has resulted in the cancer drug Kisqali), J&J and GSK and its merger with SuperGen.
  • He also advised Astellas on its Phase III product in-licence from Basilea Pharmaceuticals and was on hand to help the company through the restructuring of that deal in 2014.
  • Patrick has built up a strong relationship with GSK, and worked with it on the creation of Convergence Pharmaceuticals and Autifony Therapeutics (both funded by SV Life Sciences) and Nerre Therapeutics. He advised GSK on its 400 million Euro deal with MorphoSys.
  • Patrick has acted for Heptares for many years on a range of transactions. These include its multi-million pound drug collaboration with Genentech in 2019, its strategic multi-target partnership with Takeda Pharmaceutical Company Limited (also in 2019), and a $3.25 billion collaboration with Allergan.
  • Patrick has acted for Argenx on all of its significant partnering deals including with Leo, Abbvie and Shire.
  • Patrick advised Crescendo Biologics on its transaction with Takeda, a deal which won the Scrip licensing deal of the year for 2017.
  • Patrick also acts for a range of life science investors such as Epidarex and SROne.
  • Patrick recently advised Immunocore on its transaction with Genentech for a phase 1 ready asset.